| Nicholas Daniel Biondich, PT | |
|
1769 Lexington Ave N, 286, Roseville, MN 55113-6522 | |
| (952) 835-4512 | |
| Not Available |
| Full Name | Nicholas Daniel Biondich |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist |
| Location | 1769 Lexington Ave N, Roseville, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104862671 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 7374 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas Daniel Biondich, PT 4621 E Superior St, Duluth, MN 55804-2338 Ph: (218) 786-3550 | Nicholas Daniel Biondich, PT 1769 Lexington Ave N, 286, Roseville, MN 55113-6522 Ph: (952) 835-4512 |
News Archive
As the "recycling plant" of the cell, the proteasome regulates vitally important functions. When it is inhibited, the cell chokes on its own waste. Cancer cells, in particular, are very sensitive because they need the proteasome for their uncontrolled growth. Biochemists at the Technische Universitaet Muenchen (TUM) have now identified the lead structure of a new class of drugs that attacks the proteasome in an unusual way. New medication could be developed on the basis of this previously unknown binding mechanism.
The study will examine how much of an improvement in pain, stiffness, function and other symptoms is needed before patients consider the change important.
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system ("CNS"), including fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"), has announced the effectiveness of a company name change to Tonix Pharmaceuticals Holding Corp. and the commencement of trading under the stock symbol "TNXP".
A report in one of the last issue of Psychotherapy and Psychosomatics addresses the physical and psychological triggers for attacks in Meniere's disease.
Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV.
› Verified 8 days ago
Mr. Peter Gering Skupeko, PHYSICAL THERAPIST Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1325 Eldridge Ave W, Roseville, MN 55113 Phone: 651-639-1615 Fax: 651-639-1615 | |
David Anderson, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1955 County Road B2 W, Roseville, MN 55113 Phone: 651-697-1313 | |
Amy Sue Andersen, MPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1970 Oakcrest Ave, Suite 107, Roseville, MN 55113 Phone: 651-636-6330 | |
Rebecca Mae Gilbertson, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 2945 Lincoln Dr, Roseville, MN 55113 Phone: 651-628-3000 | |
Mr. Frederick Carl Hjelm, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1835 County Road C W, Roseville, MN 55113 Phone: 651-638-0080 Fax: 651-638-0082 | |
Grady Glynn, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 3050 Centre Pointe Dr, Suite Number 200, Roseville, MN 55113 Phone: 651-631-4242 |